PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 20 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $0 | – | 197 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 197 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 197 | -99.4% | 0.00% | – |
| Q1 2022 | $43,000 | -72.4% | 31,895 | -46.3% | 0.00% | – |
| Q4 2021 | $156,000 | +54.5% | 59,428 | +82.2% | 0.00% | – |
| Q3 2021 | $101,000 | -19.8% | 32,623 | -3.4% | 0.00% | – |
| Q2 2021 | $126,000 | +180.0% | 33,770 | +164.8% | 0.00% | – |
| Q1 2021 | $45,000 | +181.2% | 12,754 | +159.1% | 0.00% | – |
| Q4 2020 | $16,000 | -55.6% | 4,923 | -52.4% | 0.00% | – |
| Q3 2020 | $36,000 | -55.0% | 10,350 | -40.9% | 0.00% | – |
| Q2 2020 | $80,000 | +128.6% | 17,525 | +64.8% | 0.00% | – |
| Q1 2020 | $35,000 | -73.9% | 10,635 | -51.6% | 0.00% | – |
| Q4 2019 | $134,000 | +106.2% | 21,969 | +41.1% | 0.00% | – |
| Q3 2019 | $65,000 | -81.1% | 15,566 | -40.7% | 0.00% | – |
| Q2 2019 | $344,000 | +473.3% | 26,258 | +316.8% | 0.00% | – |
| Q1 2019 | $60,000 | – | 6,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |